Milestone Pharmaceuticals Company Insiders

MIST Stock  USD 1.87  0.07  3.61%   
Milestone Pharmaceuticals' insiders are aggressively buying. The analysis of insiders' sentiment of trading Milestone Pharmaceuticals stock suggests that vertually all insiders are extremely bullish at this time. Milestone Pharmaceuticals employs about 47 people. The company is managed by 13 executives with a total tenure of roughly 110 years, averaging almost 8.0 years of service per executive, having 3.62 employees per reported executive.

Milestone Pharmaceuticals' Insider Buying Vs Selling

100

 
Selling
 
Buying

Latest Trades

2022-12-05David BharuchaAcquired 7000 @ 4.69View
2022-12-01David BharuchaAcquired 3000 @ 4.86View
2022-10-21Debra K LiebertAcquired 4000 @ 5.26View
2022-10-19Robert James WillsAcquired 15000 @ 4.93View
2022-09-07Rtw Investments, LpAcquired 1557346 @ 8.71View
2022-05-31Paul F TruexAcquired 5000 @ 5.6View
Monitoring Milestone Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Milestone Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more information on how to buy Milestone Stock please use our How to Invest in Milestone Pharmaceuticals guide.

Milestone Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.3309) % which means that it has lost $0.3309 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3375) %, meaning that it created substantial loss on money invested by shareholders. Milestone Pharmaceuticals' management efficiency ratios could be used to measure how well Milestone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.83 in 2024. Return On Capital Employed is likely to drop to -0.95 in 2024. At this time, Milestone Pharmaceuticals' Liabilities And Stockholders Equity is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 468 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 6.4 M in 2024.
Common Stock Shares Outstanding is likely to drop to about 34.5 M in 2024. Net Loss is likely to drop to about (55.2 M) in 2024

Milestone Pharmaceuticals Workforce Comparison

Milestone Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 2,126. Milestone Pharmaceuticals holds roughly 47.0 in number of employees claiming about 2.21% of equities under Health Care industry.

Milestone Pharmaceuticals Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Milestone Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Milestone Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Milestone Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Milestone Pharmaceuticals Notable Stakeholders

A Milestone Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Milestone Pharmaceuticals often face trade-offs trying to please all of them. Milestone Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Milestone Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Joseph MBAPresident CEOProfile
Amit HasijaCFO DevelopmentProfile
Anita HolzVP AffairsProfile
Guy RousseauSVP ManagementProfile
FACC FAHAChief BoardProfile
Jeffrey NelsonChief OfficerProfile
Roshan GirglaniVice MarketingProfile
Kim FoxVice CommunicationsProfile
FACC MDChief OfficerProfile
Jeff NelsonChief OfficerProfile
Lorenz MullerChief OfficerProfile
Kimberly SheehanVP HRProfile
Philippe MBAStrategic FounderProfile

About Milestone Pharmaceuticals Management Performance

The success or failure of an entity such as Milestone Pharmaceuticals often depends on how effective the management is. Milestone Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Milestone management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Milestone management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.79)(0.83)
Return On Capital Employed(0.90)(0.95)
Return On Assets(0.79)(0.83)
Return On Equity(3.56)(3.38)
Please note, the imprecision that can be found in Milestone Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Milestone Pharmaceuticals. Check Milestone Pharmaceuticals' Beneish M Score to see the likelihood of Milestone Pharmaceuticals' management manipulating its earnings.

Milestone Pharmaceuticals Workforce Analysis

Traditionally, organizations such as Milestone Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Milestone Pharmaceuticals within its industry.

Milestone Pharmaceuticals Manpower Efficiency

Return on Milestone Pharmaceuticals Manpower

Revenue Per Employee21.3K
Revenue Per Executive76.9K
Net Loss Per Employee1.3M
Net Loss Per Executive4.6M
Working Capital Per Employee1.4M
Working Capital Per Executive5.1M

Additional Tools for Milestone Stock Analysis

When running Milestone Pharmaceuticals' price analysis, check to measure Milestone Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Milestone Pharmaceuticals is operating at the current time. Most of Milestone Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Milestone Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Milestone Pharmaceuticals' price. Additionally, you may evaluate how the addition of Milestone Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.